Nil Molinas Mandel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6624231/publications.pdf

Version: 2024-02-01

2258059 1872680 7 32 3 6 citations h-index g-index papers 7 7 7 81 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|---|---|-----|-----------|
| 1 | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1501-1508. | 2.5 | 3 |
| 2 | Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy. Journal of Oncology, 2020, 2020, 1-7. | 1.3 | 3 |
| 3 | Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, 2020, 37, 104-107. | 0.8 | 2 |
| 4 | Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study Journal of Clinical Oncology, 2020, 38, e13646-e13646. | 1.6 | 0 |
| 5 | Implementation of an antimicrobial stewardship program for patients with febrile neutropenia. American Journal of Infection Control, 2018, 46, 420-424. | 2.3 | 17 |
| 6 | Cytolytic tests with hyperimmune patient sera is a good prognostic tool in racotumomab immunotherapy in advanced non-small cell lung cancer. Advances in Modern Oncology Research, 2017, 3, . | 0.1 | 1 |
| 7 | Comparison of International Prognostic Index and NCCN-IPI in 324 patients with (i>de novo (li>diffuse large B-cell lymphoma: a multi-center retrospective analysis. Leukemia and Lymphoma, 2016, 57, 1211-1214. | 1.3 | 6 |